Publication: Impact of individualized management of breakthrough cancer pain on quality of life in advanced cancer patients: CAVIDIOPAL study.
Loading...
Identifiers
Date
2021-02-03
Authors
Tuca Rodríguez, Albert
Núñez Viejo, Miguel
Maradey, Pablo
Canal-Sotelo, Jaume
Guardia Mancilla, Plácido
Gutiérrez Rivero, Sonia
Raja Casillas, Inmaculada
Herrera Abián, María
López Bermudo, Cristina
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Export
Abstract
The main aim of the study was to assess the impact of individualized management of breakthrough cancer pain (BTcP) on quality of life (QoL) of patients with advanced cancer in clinical practice. A prospective, observational, multicenter study was conducted in patients with advanced cancer that were assisted by palliative care units. QoL was assessed with the EORTC QLQ-C30 questionnaire at baseline (V0) and after 28 days (V28) of individualized BTcP therapy. Data on background pain, BTcP, comorbidities, and frailty were also recorded. Ninety-three patients completed the study. Intensity, duration, and number of BTcP episodes were reduced (p Individualized BTcP therapy improved QoL of patients with advanced cancer. Transmucosal fentanyl at low doses was the most used drug. This study was registered at ClinicalTrials.gov database (NCT02840500) on July 19, 2016.
Description
MeSH Terms
Aged
Aged, 80 and over
Breakthrough Pain
Cancer Pain
Female
Humans
Male
Middle Aged
Neoplasms
Pain Management
Prospective Studies
Quality of Life
Aged, 80 and over
Breakthrough Pain
Cancer Pain
Female
Humans
Male
Middle Aged
Neoplasms
Pain Management
Prospective Studies
Quality of Life
DeCS Terms
CIE Terms
Keywords
Breakthrough cancer pain, Individualized therapy, Palliative care, Quality of life, Transmucosal fentanyl